Case Studies

In the dynamic world of biomanufacturing, the quest for improved efficiency and productivity continues to shape industry advancements. N-1 Perfusion Technology is a cutting edge innovation designed to enhance protein yield, particularly antibodies, which are critical for therapeutic applications.

The peptide therapeutics market comprises over 80 approved drugs, with many generics introduced upon patent expiration. The production of generics typically introduces additional peptide impurities. These impurities could trigger an undesired immune response, affecting safety and efficacy in patients.

Prodrugs are medications that, once administered, are metabolized in the body to release the active ingredient. They help to improve a medication’s effectiveness and can in some cases avoid certain side effects or toxicities.

The biopharmaceutical industry witnessed significant innovation, with many new recombinant protein therapeutics receiving FDA approval. However, these therapies are often costly, emphasizing the need for greater efficiency and productivity.

Learn how Syngene enabled chiral inversion analysis through integrated in vitro and in vivo studies, delivering high-quality data that advanced drug development for a targeted protein degradation program.

Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.

Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.

Learn how Syngene partnered with a global producer of specialty polymers to develop a novel, high-performance polymer for use in sustainable energy generation.

Learn how Syngene scientists scaled up a clone directly from lab scale to clinical scale and enabled clinical batch manufacturing of the product with an improved titer of >5g/L.

Learn how Syngene executed complex preclinical studies, consolidating data across pharmacokinetics, biomarker modulation, and gene expression analysis, and provided comprehensive insights for the client’s development decision on bile acid modulators for paediatric liver disease.